Brief: Galecto Announces Positive Preliminary Results For Oral Galectin-3 Inhibitor GB1211 In Part 1 Of Its Phase 1b/2a Liver Cirrhosis Trial

Damora Therapeutics

13/12/2021 13:12

Dec 13 (Reuters) - Galecto Inc  GLTO.O :
    * GALECTO ANNOUNCES POSITIVE PRELIMINARY RESULTS FOR ORAL
GALECTIN-3 INHIBITOR GB1211 IN PART 1 OF ITS PHASE 1B/2A LIVER
CIRRHOSIS TRIAL
    * GALECTO INC- GB1211 OBSERVED TO BE SAFE, WELL TOLERATED IN
INITIAL 12 RANDOMIZED SUBJECTS, INCLUDING 6 HEPATICALLY IMPAIRED
LIVER CIRRHOSIS PATIENTS
    * GALECTO INC- CO INITIATES PART 2 OF PHASE 1B/2A TRIAL OF
GB1211
IN PATIENTS WITH LIVER CIRRHOSIS
    * GALECTO INC- CO REMAIN ON TRACK TO REPORT TOP LINE DATA
FROM
FULL TRIAL OF GB1211 IN SECOND HALF OF 2022

Source text for Eikon:  ID:nGNX5qVHLX 
Further company coverage:  GLTO.O 

 ((Reuters.Briefs@thomsonreuters.com;))